Empowering patients with kidney diseases to live fuller, healthier lives.

Purespring exists to change the course of glomerular kidney diseases by providing transformative treatments to make a real difference to patient lives.

Learn More

A precision nephrology company leading the development of targeted, first-in-class genetic therapies to preserve kidney function.

Focusing on glomerular diseases with significant unmet medical need, our goal is to preserve kidney function and transform the disease trajectory so patients can live fuller, healthier lives.

>788M

people suffer from kidney disease globally

The Lancet. Projecting the economic burden of chronic kidney disease at the patient level (Inside CKD): a microsimulation modelling study

4M

patients with renal replacement therapy globally

The Lancet. Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023

3M

deaths per year from kidney disease projected by 2040

The Lancet. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories

Kidney disease remains one of humankind’s most underserved disease areas, affecting over 788 million people globally and ranking among the top 10 causes of death worldwide.

Therapeutic innovation has been lacking in renal treatments, and patients are in dire need of new options. Currently, when patients progress to end-stage renal disease, they are faced with two options, dialysis or kidney transplant, both of which are burdensome for patients, healthcare systems and society.

Recent economic modelling from the Lancet suggests the annual direct costs of diagnosed CKD and renal replacement therapies in in 31 select countries and regions will exceed US $400 bn by 2027.

At Purespring, we are re-imagining gene therapy delivery for kidney diseases, developing precisely targeted low-dose therapies that minimise systemic effects and deliver durable efficacy to transform the disease’s trajectory for patients.

Platform

Our proprietary GlomThera™ platform delivers genetic therapies directly to the kidney, offering a novel approach to the treatment of renal diseases. Designed with precision in mind, it uses a validated AAV capsid that directly targets the podocyte.

This enables dosing more than 10-fold lower than systemically administered AAV gene therapies, reducing systemic exposure while optimising the potential for therapeutic effect.

Science

Pipeline

Our pipeline targets multiple renal indications with significant unmet need.

Our aim is to leverage the versatility of our platform to develop therapies for additional glomerular diseases with unmet medical need. Our lead programme, PS-002, offers a highly differentiated approach for patients with IgA nephropathy (IgAN). IgAN is the most common primary glomerulonephritis worldwide, with an estimated global prevalence of 2.5 per 100,000 individuals.